Market Research Reports

Non-Invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi and VisibiliT) - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2014 - 2020

104pages
Published Date: 2014-11-13
 

Description



Non-invasive prenatal testing (NIPT) is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X), and also for fetal sex determination. Until recently, amniocentesis, chorionic villus sampling (CVS), maternal serum screening and nuchal translucency (NT) scan were the primary diagnostic and screening methods for chromosomal abnormalities. Advent of non-invasive prenatal test is poised to eliminate disadvantages associated with these methods, such as low rate of accuracy with maternal serum screening and NT scan, and risk of miscarriage with invasive amniocentesis and CVS procedures. This report on non-invasive prenatal testing market studies the current market scenario and future potential for non-invasive prenatal tests globally. 

The major non-invasive prenatal tests studied in this report are BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi and VisibiliT. These tests have been extensively analyzed on the basis of factors such as the technology used, cost to patients, reimbursement coverage, accuracy and geographical reach (availability across various countries). The historical market size and forecast for each of these tests in terms of revenue (USD Million) and volume (Number of tests performed) have been given in the report for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall non-invasive prenatal test market and the above tests has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. The report on non-invasive prenatal testing market also provides comparative analysis of major tests for the years 2013 and 2020.

In this research study, the global market for non-invasive prenatal testing has been geographically segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The non-invasive prenatal testing market size and forecast in terms of revenue (USD Million) and volume (Number of Tests Performed) for each region has been provided for the period 2012 to 2020 along with the CAGR for the forecast period 2014 to 2020. The non-invasive prenatal testing market study also includes qualitative analysis of the competitive scenario in these regions such as major collaboration and partnership, entry of new entrants, new product launch and other macro economic factors. The market overview section of the report on non-invasive prenatal testing market comprises qualitative analysis of the overall non-invasive prenatal testing market considering the factors determining the market dynamics such as drivers, restraints and opportunities along with the Porter’s five force analysis and market attractiveness analysis. The market overview chapter also provides information such as major chromosomal aneuploidies (Down syndrome, Edwards syndrome, Patau syndrome and monosomy X, and their incidence rate, technological approach for NIPT and major patents issued to players operating in the market and other companies and academic research institutions.

The report also includes a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global non-invasive prenatal testing market, in terms of percentage share in 2013 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the non-invasive prenatal testing market and accentuate market shares. The report concludes with the profiles of major players in the NIPT market such as Sequenom, Inc., Ariosa Diagnostics, Natera, Inc., Illumina, Inc. (Verinata Health, Inc.), BGI Diagnostics, LifeCodexx AG, Laboratory Corporation of America Holdings (LabCorp) and Berry Genomics. Each company profile comprises information such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global non-invasive prenatal testing market is segmented as follows:

Non-Invasive Prenatal Testing Market, by Test
  • BambniTest
  • Harmony
  • informaSeq
  • MaterniT21 PLUS
  • NIFTY
  • Panorama
  • PrenaTest
  • verifi
  • VisibiliT
Non-Invasive Prenatal Testing Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2013 & 2020)
2.2 Global Non-Invasive Prenatal Testing Market, by Test, 2013 (USD Million)
2.3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2013 & 2020 (Value %)
2.4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2013 & 2020 (Volume %)

Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
3.1 Introduction
3.2 Major Chromosomal Aneuploidies and their Incidence Rate
      3.2.1 Down Syndrome
      3.2.2 Edwards Syndrome
      3.2.3 Patau Syndrome
      3.2.4 Turner Syndrome
      3.2.5 Klinefelter Syndrome
      3.2.6 Jacobs Syndrome
      3.2.7 Triple X Syndrome
3.3 Technological Approach for NIPT
3.4 Patent Landscape
      3.4.1 Major Patents issued to Sequenom, Inc.
      3.4.2 Major Patents issued to Ariosa Diagnostics, Inc.
      3.4.3 Major Patents issued to Natera, Inc.
      3.4.4 Major Patents issued to Verinata Health, Inc. (Illumina, Inc.)
      3.4.5 Major Patents issued to Cellscape Corporation
      3.4.6 Others
3.5 Market Drivers
      3.5.1 High incidence rate of babies born with Down syndrome
      3.5.2 Globally rising average maternal age
      3.5.3 Increasing demand for early and non-invasive fetal testing procedures
3.6 Market Restraints
      3.6.1 Regulatory guidelines and ethical hurdles
      3.6.2 Limitations of NIPT
      3.6.3 Availability of other screening and testing methods
3.7 Market Opportunities
      3.7.1 Capitalizing on the potential presented by the emerging market of Europe
3.8 Porter’s Five Force Analysis for the Global Non-Invasive Prenatal testing Market
      3.8.1 Bargaining power of suppliers
      3.8.2 Bargaining power of buyers
      3.8.1 Threat of substitutes
      3.8.2 Threat of new entrants
      3.8.3 Competitive rivalry
3.9 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography

Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Test
4.1 Overview
      4.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2020 (USD Million)
      4.1.2 Global Non-Invasive Prenatal Testing Market Volume, by Test, 2012 – 2020 (Number of Tests Performed)
      4.1.3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2013 & 2020 (Value %)
      4.1.4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Test, 2013 & 2020 (Volume %)
4.2 BambniTest
      4.2.1 Global BambniTest Test Market Revenue, 2012 – 2020 (USD Million)
      4.2.2 Global BambniTest Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.3 Harmony Prenatal Test
      4.3.1 Global Harmony Test Market Revenue, 2012 – 2020 (USD Million)
      4.3.2 Global Harmony Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.4 informaSeq Prenatal Test
      4.4.1 Global informaSeq Test Market Revenue, 2014 – 2020 (USD Million)
      4.4.2 Global informaSeq Test Market Volume, 2014 – 2020 (Number of Tests Performed)
4.5 MaterniT21 PLUS
      4.5.1 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2020 (USD Million)
      4.5.2 Global MaterniT21 PLUS Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.6 Noninvasive Fetal Trisomy (NIFTY) Test
      4.6.1 Global NIFTY Test Market Revenue, 2012 – 2020 (USD Million)
      4.6.2 Global NIFTY Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.7 Panorama Test
      4.7.1 Global Panorama Test Market Revenue, 2012 – 2020 (USD Million)
      4.7.2 Global Panorama Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.8 PrenaTest
      4.8.1 Global PrenaTest Test Market Revenue, 2012 – 2020 (USD Million)
      4.8.2 Global PrenaTest Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.9 verifi
      4.9.1 Global verifi Test Market Revenue, 2012 – 2020 (USD Million)
      4.9.2 Global verifi Test Market Volume, 2012 – 2020 (Number of Tests Performed)
4.10 VisibiliT Test
      4.10.1 Global VisibiliT Test Market Revenue, 2014 – 2020 (USD Million)
      4.10.2 Global VisibiliT Test Market Volume, 2014 – 2020 (Number of Tests Performed)

Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Geography
5.1 Overview
      5.1.1 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2020 (USD Million)
      5.1.2 Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2012 - 2020 (Number of Tests Performed)
5.2 North America
      5.2.1 North America Non-Invasive Prenatal Testing Market Revenue, 2012 - 2020 (USD Million)
      5.2.2 North America Non-Invasive Prenatal Testing Market Volume, 2012 - 2020 (Number of Tests Performed)
5.3 Europe
      5.3.1 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 - 2020 (USD Million)
      5.3.2 Europe Non-Invasive Prenatal Testing Market Volume, 2012 - 2020 (Number of Tests Performed)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 - 2020 (USD Million)
      5.4.2 Asia-Pacific Non-Invasive Prenatal Testing Market Volume, 2012 - 2020 (Number of Tests Performed)
5.5 Rest of the World (RoW)
      5.5.1 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 - 2020 (USD Million)
      5.5.2 RoW Non-Invasive Prenatal Testing Market Volume, 2012 - 2020 (Number of Tests Performed)

Chapter 6 Competitive Landscape
6.1 Market Share Analysis, by Key Players, 2013 (%)

Chapter 7 Recommendations
7.1 Focus on improving technology in order to increase the accuracy, reduce the duration of result generation and price
7.2 Focus on forming alliances with diagnostic service providers in Europe and Asia-Pacific countries
7.3 Mergers and acquisitions

Chapter 8 Company Profiles
8.1 Ariosa Diagnostics, Inc.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Berry Genomics Co., Ltd
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 BGI Diagnostics
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 LabCorp
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 LifeCodexx AG
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Natera, Inc.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Sequenom, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Illumina, Inc.
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Recent Developments

List of Figures

FIG. 1 Non-Invasive Prenatal Testing: Market Segmentation
FIG. 2 Global Non-Invasive Prenatal Testing Market, by Test, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2013 & 2020 (Volume %)
FIG. 5 Porter’s Five Force Analysis: Global Non-Invasive Prenatal Testing Market
FIG. 6 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography
FIG. 7 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2013 & 2020 (Value %)
FIG. 8 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Volume, by Test, 2013 & 2020 (Volume %)
FIG. 9 Global BambniTest Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global BambniTest Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 11 Global Harmony Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Harmony Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 13 Global informaSeq Test Market Revenue, 2014 – 2020 (USD Million)
FIG. 14 Global informaSeq Test Market Volume, 2014 – 2020 (Number of Tests Performed)
FIG. 15 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global MaterniT21 PLUS Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 17 Global NIFTY Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Global NIFTY Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 19 Global Panorama Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Global Panorama Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 21 Global PrenaTest Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Global PrenaTest Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 23 Global verifi Test Market Revenue, 2012 – 2020 (USD Million)
FIG. 24 Global verifi Test Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 25 Global VisibiliT Test Market Revenue, 2014 – 2020 (USD Million)
FIG. 26 Global VisibiliT Test Market Volume, 2014 – 2020 (Number of Tests Performed)
FIG. 27 North America Non-Invasive Prenatal Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 28 North America Non-Invasive Prenatal Testing Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 29 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 30 Europe Non-Invasive Prenatal Testing Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 31 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 32 Asia-Pacific Non-Invasive Prenatal Testing Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 33 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 34 RoW Non-Invasive Prenatal Testing Market Volume, 2012 – 2020 (Number of Tests Performed)
FIG. 35 Non-Invasive Prenatal Testing: Market Share, by Key Players, 2013 (%)
FIG. 36 LabCorp: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 37 Sequenom, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)

FIG. 1 Non-Invasive Prenatal Testing: Market Segmentation
FIG. 2 Global Non-Invasive Prenatal Testing Market, by Test, 2012 (USD Million)
FIG. 3 Porter’s Five Force Analysis: Global Non-Invasive Prenatal Testing Market
FIG. 4 Market Attractiveness Analysis: Global Non-Invasive Prenatal Testing Market, by Geography (2012)
FIG. 5 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 & 2019 (Value %)
FIG. 6 Global MaterniT21 PLUS Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 7 Global Harmony Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 8 Global verifi Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 9 Global Panorama Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 10 Global NIFTY Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 11 Global BambniTest Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 12 Global PrenaTest Test Market Revenue, 2012 – 2019 (USD Million)
FIG. 13 Comparative Analysis: Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 14 North America Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 15 Europe Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 16 Asia-Pacific Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 17 RoW Non-Invasive Prenatal Testing Market Revenue, 2012 – 2019 (USD Million)
FIG. 18 Non-Invasive Prenatal Testing: Market Share, by Key Players, 2012 (%)
FIG. 19 Annual Revenue: Sequenom, Inc., 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2013 & 2020)
TABLE 2 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2020 (USD Million)
TABLE 3 Global Non-Invasive Prenatal Testing Market Volume, by Test, 2012 – 2020 (Number of Tests Performed)
TABLE 4 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 5 Global Non-Invasive Prenatal Testing Market Volume, by Geography, 2012 – 2020 (Number of Tests Performed)
TABLE 6 Ariosa Diagnostics, Inc.: Expenses & Revenue, 2011 – 2013 (USD Thousands)
TABLE 7 Sequenom, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)

TABLE 1 Market Snapshot: Global Non-Invasive Prenatal Testing (NIPT) Market (2012 & 2019)
TABLE 2 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 – 2019 (USD Million)
TABLE 3 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 – 2019 (USD Million)

Enquiry Before Buying


Free Market Analysis


Non-invasive prenatal testing is increasingly being adopted by high risk pregnant women for screening of common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (monosomy X) and many others. The non-invasive nature of these tests, their accuracy and safety have been the major reasons behind their popularity among gynecologists and expecting mothers. MaterniT21 (now known as MaterniT21 PLUS) was the first NIPT launched in October 2011, by U.S. based Sequenom, Inc. and since then has been leading the market with the largest market share in terms of revenue as well as volume (number of tests performed in a year). However, by the end of 2014, BGI’s NIFTY is expected to surpass MaterniT21 PLUS in terms of volume in the global market. In North America region, Sequenom, Inc. is likely to maintain its leadership position through 2020. Harmony, verifi, Panorama, informaSeq, VisibiliT, PrenaTest and BambniTest are other commercially available NIPTs for detecting chromosomal abnormalities.

The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). As maternal age is closely associated with the increasing risk of developing a fetus with chromosomal abnormalities, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies. According to Down Syndrome Education (DSE), in the U.S., the incidence rate for Down syndrome is 1 in every 830 child births (around 4,700 annually), while in Europe the incidence rate is 1 in every 920 babies born (around 9,000 annually), indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the chance of miscarriage, which is the prime reason for their replacement with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.

North America held the largest share in the global NIPT market in terms of revenue as well as volume in 2013, accounting for 58.8% and 51.0%, respectively of the total NIPT market. The fact that the major players are U.S. based and have relatively high awareness levels in the North American region about NIPT is the key factors responsible for the region’s leadership position. In Europe, the market growth largely relies on the increasing penetration of these U.S. based test developers and the expected increase in acceptance of these tests. In the Asia-Pacific market, Japan, Australia, China and India represent the high growth potential markets. The presence of a large population of women preferring late pregnancy is likely to act as one of the major growth drivers in the region. In China, the market is dominated by two local players, namely, BGI Diagnostics and Berry Genomics.

Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera, Inc., BGI Health, LifeCodexx AG, LabCorp and Berry Genomics are the key players competing in the market for non-invasive prenatal testing. These players operate by marketing their proprietary non-invasive prenatal tests by forming alliances with hospitals, clinical laboratories and physician offices.

global-non-invasive-prenatal-testing-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research